ArticleViruses2020
Parenterally Administered Porcine Epidemic Diarrhea Virus-Like Particle-Based Vaccine Formulated with CCL25/28 Chemokines Induces Systemic and Mucosal Immune Protectivity in Pigs.
Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Overcoming Antigenic Drift in PEDV: Broadly Protective Antigen Design and sIgA-Driven Lactogenic Immunity.Veterinary sciences · 2026Review
- Swine Enteric Coronaviruses: An Updated Overview of Epidemiology, Diagnosis, Prevention, and Control.Animals : an open access journal from MDPI · 2026Review
- Role of mucosal chemokines in the development of tissue-resident CD4Frontiers in immunology · 2026Review
- A Systematic Review and Meta-Analysis of Porcine Epidemic Diarrhea Virus Vaccine Efficacy and Its Modifiers.Animals : an open access journal from MDPI · 2025Review
- Farm animal coronaviruses: the solution is in vaccines.The veterinary quarterly · 2025Review
- Fucoidan Alleviates Porcine Epidemic Diarrhea Virus-Induced Intestinal Damage in Piglets by Enhancing Antioxidant Capacity and Modulating Arginine Metabolism.Animals : an open access journal from MDPI · 2025Article
- Research progress and strategies for vaccines and targeted drugs against highly virulent porcine epidemic diarrhea virus.Frontiers in microbiology · 2025Review
- Next-Generation Vaccines for Co-Circulating PEDV and TGEV: Integrating Nucleic Acid Platforms, Mucosal Delivery, and AI-Driven Antigen Design.Transboundary and emerging diseases · 2025Review
- Review
- Research progress of porcine epidemic diarrhea virus S protein.Frontiers in microbiology · 2024Review
- Genetically Engineered Microorganisms and Their Impact on Human Health.International journal of clinical practice · 2024Review
- Transcriptomics yields valuable information regarding the response mechanisms of Chinese Min pigs infected with PEDV.Frontiers in veterinary science · 2023Article
- Self-Assembly of Porcine Parvovirus Virus-like Particles and Their Application in Serological Assay.Viruses · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generation of a safe, economical, and effective vaccine capable of inducing mucosal immunity is critical for the development of vaccines against enteric viral diseases. In the current study, virus-like particles (VLPs) containing the spike (S), membrane (M), and envelope (E) structural proteins of porcine epidemic diarrhea virus (PEDV) expressed by the novel polycistronic baculovirus expression vector were generated. The immunogenicity and protective efficacy of the PEDV VLPs formulated with or without mucosal adjuvants of CCL25 and CCL28 (CCL25/28) were evaluated in post-weaning pigs. While pigs intramuscularly immunized with VLPs alone were capable of eliciting systemic anti-PEDV S-specific IgG and cellular immunity, co-administration of PEDV VLPs with CCL25/28 could further modulate the immune responses by enhancing systemic anti-PEDV S-specific IgG, mucosal IgA, and cellular immunity. Upon challenge with PEDV, both VLP-immunized groups showed milder clinical signs with reduced fecal viral shedding as compared to the control group. Furthermore, pigs immunized with VLPs adjuvanted with CCL25/28 showed superior immune protection against PEDV. Our results suggest that VLPs formulated with CCL25/28 may serve as a potential PEDV vaccine candidate and the same strategy may serve as a platform for the development of other enteric viral vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.